Clinical Cancer Research, Vol 4, Issue 5 1221-1225, Copyright © 1998 by American Association for Cancer Research

ARTICLES

Evaluation of the balance between angiogenic and antiangiogenic circulating factors in patients with breast and gastrointestinal cancers

D Morelli, D Lazzerini, S Cazzaniga, P Squicciarini, P Bignami, JA Maier, L Sfondrini, S Menard, MI Colnaghi and A Balsari
Division of Experimental Oncology, Istituto Nazionale Tumori, Milan, Italy.

Angiogenesis is a critical determinant of tumor growth. Tumor cells produce or induce angiogenic molecules that act specifically on endothelial cells (ECs) but also release angiostatic molecules. Thus, tumor angiogenesis represents a net balance between positive and negative regulators of neovascularization. Sera from patients with breast or gastrointestinal cancers were evaluated for their capacity to selectively modulate the proliferation of human umbilical vein ECs; sera from 15 of 78 (19%) breast cancer patients and 8 of 53 (15%) gastrointestinal cancer patients induced human umbilical vein EC growth, whereas sera from 4 of 78 (5%) breast cancer patients and 1 of 53 (2%) gastrointestinal cancer patients inhibited EC proliferation. Growth-stimulatory sera were significantly more frequent among postmenopausal (14 of 53) than premenopausal (1 of 25) breast cancer patients; inhibitory activity was observed in 3 of 25 premenopausal patients versus 1 of 53 postmenopausal individuals. The half-life of serum-stimulating and -inhibiting factors seemed to differ, because stimulatory activity but not inhibitory activity was decreased at 5 days after surgery. The levels of vascular endothelial growth factor were elevated in about 45% of patients with growth-stimulatory sera, whereas the serum inhibition of EC growth was found to be due, at least in part, to high levels of soluble thrombospondin.

This article has been cited by other articles:

				Y.-W. Tien, K.-J. Chang, Y.-F. Chiu, K.-W. Huang, and P.-H. Lee Comparison of Angiogenic Factor Levels in Tumor Drainage and Peripheral Venous Blood From Colorectal Cancer Patients Ann. Surg. Oncol., November 1, 2006; 13(11): 1357 - 1363. [Abstract] [Full Text] [PDF]

				K. Tanaka, H. Sonoo, J. Kurebayashi, T. Nomura, S. Ohkubo, Y. Yamamoto, and S. Yamamoto Inhibition of Infiltration and Angiogenesis by Thrombospondin-1 in Papillary Thyroid Carcinoma Clin. Cancer Res., May 1, 2002; 8(5): 1125 - 1131. [Abstract] [Full Text] [PDF]

				E. Fosslien Molecular Pathology of Cyclooxygenase-2 in Cancer-induced Angiogenesis Ann. Clin. Lab. Sci., October 1, 2001; 31(4): 325 - 348. [Abstract] [Full Text] [PDF]

				S. Filleur, O. V. Volpert, A. Degeorges, C. Voland, F. Reiher, P. Clezardin, N. Bouck, and F. Cabon In vivo mechanisms by which tumors producing thrombospondin 1 bypass its inhibitory effects Genes & Dev., June 1, 2001; 15(11): 1373 - 1382. [Abstract] [Full Text] [PDF]

				R. T.-P. Poon, S.-T. Fan, and J. Wong Clinical Implications of Circulating Angiogenic Factors in Cancer Patients J. Clin. Oncol., February 15, 2001; 19(4): 1207 - 1225. [Abstract] [Full Text] [PDF]

				L. Chandrasekaran, C.-Z. He, H. Al-Barazi, H. C. Krutzsch, M. L. Iruela-Arispe, and D. D. Roberts Cell Contact-dependent Activation of alpha 3beta 1 Integrin Modulates Endothelial Cell Responses to Thrombospondin-1 Mol. Biol. Cell, September 1, 2000; 11(9): 2885 - 2900. [Abstract] [Full Text]

				S. Ramanujan, G. C. Koenig, T. P. Padera, B. R. Stoll, and R. K. Jain Local Imbalance of Proangiogenic and Antiangiogenic Factors: A Potential Mechanism of Focal Necrosis and Dormancy in Tumors Cancer Res., March 1, 2000; 60(5): 1442 - 1448. [Abstract] [Full Text]